Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg

NCT01539213 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Psoriasis

Interventions

DRUG: secukinumab (AIN457)

Sponsor

Novartis Pharmaceuticals